Summary by Futu AI
DISCLOSED IN ITS 2023 ANNUAL REPORT, CONXINO BIO ACHIEVED OPERATING REVENUE OF $3.57 MILLION, DOWN 65.49% YEAR-ON-YEAR, NET MATERNITY LOSS OF $14.83 BILLION, A YEAR-ON-YEAR LOSS OF 63.04%, GROSS MARGIN FROM PRIMARY BUSINESS WAS 26.50%, AND SALES REVENUE FOR CORONAVIRUS PRODUCTS DECREASED 96.86%. Based on the actual and expected return of the COVID-19 vaccine, the company reported a revenue reduction of $2.53 million. In addition, the company's balance of accounts receivable totaled $6.63 billion, of which 27.80% of accounts receivable for more than 1 year and 0.67% in 2022, respectively. The company explained that the recovery of receivables related to the COVID-19 vaccine was slower, resulting in an increase in the proportion of receivables for more than 1 year. As for the capital situation of the company, the company...Show More